| MANUFACTURING |
Contract Manufacturer had first to prove it could cut the active’s cost, & this was difficult because the later stages of production are laid out in regulatory documents & can’t be changed. Instead supplier Co. through some 5,000 experiments conducted over the course of a year, Supplier Co.’s chemists came up with new routes to the 3 key starting materials required for the later stages, lowering costs. “We met their price target”
Co subsequently invested $20 million in a new plant in Bavla, India for the drug. Late last month Drug owner’s Co audited the facility & signed contracts that will worth roughly $15 million this year & potentially $500 million throughout the life of the drug’s patent which wxpires in 2013
|